NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
Neurogene Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$24.17+0.92 (+3.96%)
Close on Oct 19, 2026
- Market cap
- $545.08M
- P/E (TTM)
- –
- Dividend yield
- –
Neurogene statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Neurogene | Industry median |
|---|---|---|
| Market Cap | $483.68M | $197.05M |
| Enterprise Value | $258.28M | $106.56M |
| PB Ratio | 2.23 | 2.14 |
| P/TBV Ratio | 2.23 | 2.46 |
Income (trailing twelve months)
| Measure | Neurogene | Industry median |
|---|---|---|
| Operating Income | -$121.35M | -$21.44M |
| Net Income | -$111.11M | -$22.46M |
| EBITDA | -$118.11M | -$16.91M |
| EPS (Diluted) | -$5.03 | -$0.83 |
Returns
| Measure | Neurogene | Industry median |
|---|---|---|
| Return on Equity (ROE) | -45.3% | -53.1% |
| Return on Assets (ROA) | -41.0% | -41.0% |
| Return on Capital Employed (ROCE) | -54.4% | -37.8% |
Balance sheet
| Measure | Neurogene | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $225.39M | $62.42M |
| Net Cash (Debt) | $225.39M | $15.68M |
| Net Cash Per Share | $11.26 | $0.65 |
| Equity (Book Value) | $217.13M | $48.79M |
| Book Value Per Share | $10.85 | $1.36 |
| Tangible Book Value | $217.13M | $23.06M |
| Working Capital | $207.41M | $75.77M |
Financial position
| Measure | Neurogene | Industry median |
|---|---|---|
| Current Ratio | 10.64 | 3.30 |
| Quick Ratio | 10.48 | 2.39 |
| Interest Coverage | -60673.00 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Neurogene | Industry median |
|---|---|---|
| Operating Cash Flow | -$86.82M | -$12.35M |
| Capital Expenditures | -$890.00K | -$1.06M |
| Free Cash Flow | -$87.71M | -$20.28M |
| FCF Per Share | -$4.38 | -$0.41 |
Efficiency
| Measure | Neurogene | Industry median |
|---|---|---|
| Profits Per Employee | -$848.17K | -$732.08K |
| Employee Count | 131 | 73 |
Dividends and yields
| Measure | Neurogene | Industry median |
|---|---|---|
| Earnings Yield | -23.0% | -21.2% |
| FCF Yield | -18.1% | -7.64% |
Shares
| Measure | Neurogene | Industry median |
|---|---|---|
| Shares Outstanding | 20,011,400 | 59,128,900 |
| Shares Change (YoY) | 12.3% | 11.1% |
| Shares Change (QoQ) | 1.38% | 0.54% |
| Float | 16,822,900 | 48,744,500 |
| Shares Held by Insiders | 15.9% | 11.8% |
| Shares Held by Institutions | 86.5% | 59.4% |
Scores
| Measure | Neurogene | Industry median |
|---|---|---|
| Altman Z-Score | 7.64 | 0.10 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Neurogene's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.